BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14636304)

  • 1. Four peptides decrease the number of human pancreatic adenocarcinoma cells.
    Vesely BA; McAfee Q; Gower WR; Vesely DL
    Eur J Clin Invest; 2003 Nov; 33(11):998-1005. PubMed ID: 14636304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four peptide hormones decrease the number of human breast adenocarcinoma cells.
    Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Solivan SM; Gower WR; Vesely DL
    Eur J Clin Invest; 2005 Jan; 35(1):60-9. PubMed ID: 15638821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.
    Gower WR; Vesely BA; Alli AA; Vesely DL
    Int J Gastrointest Cancer; 2005; 36(2):77-87. PubMed ID: 16648657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five cardiac hormones decrease the number of human small-cell lung cancer cells.
    Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Alli AA; Solivan SM; Gower WR; Vesely DL
    Eur J Clin Invest; 2005 Jun; 35(6):388-98. PubMed ID: 15948900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells.
    Vesely BA; Fitz SR; Gower WR; Vesely DL
    Cancer Lett; 2006 Feb; 233(2):226-31. PubMed ID: 15893414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approach for cancer using four cardiovascular hormones.
    Vesely DL; Clark LC; Garces AH; McAfee QW; Soto J; Gower WR
    Eur J Clin Invest; 2004 Oct; 34(10):674-82. PubMed ID: 15473892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells.
    Vesely BA; Alli AA; Song SJ; Gower WR; Sanchez-Ramos J; Vesely DL
    Eur J Clin Invest; 2005 Nov; 35(11):700-10. PubMed ID: 16269020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Skelton WP; Lenz A; Wang H; Vesely DL
    Anticancer Res; 2009 Apr; 29(4):971-5. PubMed ID: 19414334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial natriuretic peptides: anticancer agents.
    Vesely DL
    J Investig Med; 2005 Nov; 53(7):360-5. PubMed ID: 16297362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2006; 26(5A):3217-22. PubMed ID: 17094432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2007; 27(3B):1387-92. PubMed ID: 17595752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells.
    Vesely BA; Alli A; Song S; Sanchez-Ramos J; Fitz SR; Gower WR; Vesely DL
    Cardiology; 2006; 105(4):226-33. PubMed ID: 16534199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four cardiac hormones eliminate 4-fold more human glioblastoma cells than the green mamba snake peptide.
    Vesely BA; Eichelbaum EJ; Alli AA; Sun Y; Gower WR; Vesely DL
    Cancer Lett; 2007 Aug; 254(1):94-101. PubMed ID: 17399891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac hormones inhibit proliferation of pancreatic cancer but not normal cells.
    Skelton WP; Pi G; Lenz A; Sun Y; Vesely DL
    Eur J Clin Invest; 2010 Aug; 40(8):706-12. PubMed ID: 20546014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.
    Chiou S; Vesely DL
    Endocrinology; 1995 May; 136(5):2033-9. PubMed ID: 7720651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ras in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Lenz A; Skelton WP; Wang H; Vesely DL
    Anticancer Res; 2009 Jun; 29(6):1889-93. PubMed ID: 19528444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
    Vesely DL; San Miguel GI; Hassan I; Schocken DD
    Horm Metab Res; 2002 May; 34(5):245-9. PubMed ID: 12063637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.
    Vesely DL; Perez-Lamboy GI; Schocken DD
    Metabolism; 2000 Dec; 49(12):1592-7. PubMed ID: 11145122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas.
    Saba SR; Garces AH; Clark LC; Soto J; Gower WR; Vesely DL
    J Histochem Cytochem; 2005 Aug; 53(8):989-95. PubMed ID: 15879575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of AKT in human pancreatic, renal and colorectal cancer cells by four cardiac hormones.
    Skelton WP; Skelton M; Vesely DL
    Anticancer Res; 2013 Mar; 33(3):785-90. PubMed ID: 23482745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.